Effect of initial drug choice on persistence with antihypertensive therapy: The importance of actual practice data

CMAJ. Canadian Medical Association Journal

Volumn 160, Issue 1, 1999, Pages 41-46

  Caro, J Jaime ^a,b,d   Speckman, Jeanne L ^a   Salas, Maribel ^a   Raggio, Gabriel ^a   Jackson, Joseph D ^c  

^a CARO RESEARCH INSTITUTE   (United States)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CANADA; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FEMALE; HEALTH STATUS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; OUTPATIENT; PATIENT COMPLIANCE;

EID: 0033547741     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. 1. Hiatt H, Goldman L. Making medicine more scientific. Nature 1994;371:100.
2. 2. Gibaldi M. Evidence based medicine and cost effectiveness. Univ Wash Pharm Outcomes Res Policy Program Rep 1997;3:1-3.
3. 3. Purpose and procedure. Evidence Based Med 1996;1:98-9.
4. 4. Sobel B, Furberg C. Surrogates, semantics, and sensible public policy. Circulation 1997;95:1661-3.
5. 5. Neaton JD, Grimm RH, Prineas RJ, Stamier J, Grandits GA, Elmer PJ, et al. Treatment of mild hypertension study. Final results. JAMA 1993;270:713-24. [Leanne looked this ref up for Myers; 4th author is Stamler; also "Treatment of Mild Hypertension Study" is a formal name, and MEDLINE lists "Treatment of Mild Hypertension Study Research Group" at the end of the title]
6. 6. Caro JJ, Salas M, Speckman JL, Raggio GD, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ 1999;160:31-7
7. 7. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, et al. Discontinuation of antihyperlipidemic drugs - Do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332: 1125-31.
8. 8. Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A. Blood pressure control in the hypertensive population. Lancet 1997;349:454-7.
9. 9. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: Is the "rule of halves" still valid? J Hum Hypertens 1997;11:213-20.
10. 10. Goldstein AO, Carey TS, Levis D, Madson S, Bernstein J. Variations in hypertension control in indigent rural primary care clinics in North Carolina. Arch Fam Med 1994;3:514-19.
11. 11. Stockwell DH, Madhavan S, Cohen H, Gibson G, Alderman MH. The determinants of hypertension awareness, treatment and control in an insured population. Am J Public Health 1994;84:1768-74.
12. 12. Black DM, Brand RJ, Greenlick M, Hughes G, Smith J, for the SHEP Pilot Research Group. Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. J Gerontol 1987;42:552-7.
13. 13. Hershey JC, Morton BG, Davis JB, Reichgott MJ. Patient compliance with antihypertensive medication. Am J Public Health 1980;70:1081-9.
14. 14. Nelson EC, Stason WB, Neutra RR, Solomons HS. Identification of the non-compliant hypertensive patient. Prev Med 1980;9:504-17.
15. 15. Malcolm E, Downey W, Stand LM, McNutt M, West R. Saskatchewan Health's linkable data bases and pharmacoepidemiology. Post Mark Surveillance 1993;6:175-264.
16. 16. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons; 1980. p. 10-9.
17. 17. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC-V). Arch Intern Med 1993;153:154-83.
18. 18. Ogilvie RI, Burgess ED, Cusson JR, Feldman RD, Leiter LA, Myers MG. Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of essential hypertension. CMAJ 1993;149:575-84.
19. 19. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group Report on hypertension in the elderly. Hypertension 1994;23:275-85.
20. 20. Williams GH. Hypertensive vascular disease. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fanci AS, Kasper DL, et al, editors. Harrison's principles of internal medicine. New York: McGraw-Hill; 1994.
21. 21. Reeves RA. Does this patient have hypertension? How to measure blood pressure. JAMA 1995;273:1211-8.
22. 22. Pierdomenico SD, Mezzetti A, Lapenna D, Guglielmi MD, Mancini M, Salvatori I, et al. "White-coat" hypertension in patients with newly diagnosed hypertension: evaluation of prevalence by ambulatory monitoring and impact on cost of health care. Eur Heart J 1995;16:692-7.
23. 23. Rawson NS, Malcolm E. Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafiles. Stat Med 1995;14:2627-43.
24. 24. Rawson NS, Malcolm E, D'Arcy C. Reliability of the recording of schizophrenia and depressive disorder in the Saskatchewan health care datafiles. Soc Psychiatry Psychiatr Epidemiol 1997;32:191-9.
25. 25. Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995;311:293-5.
26. 26. Hamilton RA, Briceland LL. Use of prescription-refill records to assess patient compliance. Am J Hosp Pharm 1992;49:1691-6.
27. 27. Elliott WJ. Discontinuation rates for ACE inhibitors and calcium antagonists in a tertiary hypertension clinic [abstract]. Am J Hypertens 1993;6:94A.
28. 28. Shea S, Misra D, Ehrlich MG, Field L, Francis CK. Correlates of nonadherence to hypertension treatment in an inner-city minority population. Am J Public Health 1992;82:1607-12.
29. 29. Sharkness CM, Snow DA. The patient's view of hypertension and compliance. Am J Prev Med 1992;8:141-6.
30. 30. Cooper JK, Love DW, Raffoul PR. Intentional prescription nonadherence (noncompliance) by the elderly. J Am Geriatr Soc 1982;30:329-33.
31. 31. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens 1997;10(7 pt 1):697-704.